CST3 and acute kidney injury: Therefore, prospective intervention trials are necessary to prove if early risk-assessment with Cystatin C and risk-adjusted management can reduce AKI incidence, severity or progression and associated mortality after thoracic aortic surgery with moderate hypothermic circulatory arrest.